Leto Laura, Aspromonte Nadia, Feola Mauro
Scuola di Specializzazione in Geriatria, Universita degli Studi, Torino.
G Ital Cardiol (Rome). 2012 Apr;13(4):263-72. doi: 10.1714/1056.11558.
Intravenous loop diuretics are increasingly used to treat symptoms and signs of fluid overload in acute heart failure, a clinical condition associated with high morbidity and mortality rates. Although diuretic therapy is widely used and strongly recommended by most recent clinical guidelines, prospective studies and randomized clinical trials are lacking and hence there is no reliable evidence regarding the best therapy in terms of doses, ways and methods of administration. With heart failure progression, the efficacy of loop diuretics is impaired by diuretic resistance characterized by a decreased diuretic and natriuretic effect of drugs. This review focuses on the current management of acute heart failure with diuretic therapy. Continuous diuretic infusion seems to be a good choice, from a pharmacokinetic point of view, when fluid overload is refractory to conventional therapy. Several available studies comparing bolus injection to continuous infusion of loop diuretics proved the latter to be an effective and safe method of administration. Continuous infusion seems to produce a constant plasma drug concentration with a more uniform daily diuretic and natriuretic effect and a greater safety profile (fewer adverse events such as worsening renal failure, electrolyte imbalance, ototoxicity). In addition, the analysis of available literature data did not provide conclusive evidence about the effects on clinical outcomes (mortality, rehospitalization rates, adverse events).
静脉注射袢利尿剂越来越多地用于治疗急性心力衰竭中液体超负荷的症状和体征,这是一种发病率和死亡率都很高的临床病症。尽管利尿剂疗法被广泛使用且被最新临床指南强烈推荐,但前瞻性研究和随机临床试验却很缺乏,因此在剂量、给药途径和方法方面,没有关于最佳治疗方案的可靠证据。随着心力衰竭的进展,袢利尿剂的疗效会因利尿剂抵抗而受损,其特征为药物的利尿和排钠作用降低。本综述聚焦于利尿剂疗法对急性心力衰竭的当前管理。从药代动力学角度来看,当液体超负荷对传统治疗无效时,持续静脉输注利尿剂似乎是个不错的选择。多项比较袢利尿剂大剂量注射与持续输注的现有研究证明,后者是一种有效且安全的给药方法。持续输注似乎能产生恒定的血浆药物浓度,具有更均匀的每日利尿和排钠作用,且安全性更高(如肾衰竭恶化、电解质失衡、耳毒性等不良事件更少)。此外,对现有文献数据的分析并未提供关于对临床结局(死亡率、再住院率、不良事件)影响的确凿证据。